Powered by

Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome

Aug 14, 2019 - GlobeNewswire
Mergers and Acquisitions-Partnership Announcement

Program aims to be first disease-modifying treatment for this serious neurogenetic disorder

Ultragenyx receives an exclusive option to acquire GeneTx

NOVATO, Calif. and DOWNERS GROVE, Ill., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, and GeneTx Biotherapeutics LLC, today announced a partnership to develop GeneTx's GTX-102, an antise...